Cargando…
Curative-Intent Treatment with Durvalumab in Early-Stage Cancers
The introduction of immunotherapy has fundamentally transformed the treatment landscape in cancer, providing long-term survival benefit for patients with advanced disease across multiple tumor types, including non-small cell lung cancer (NSCLC). In the placebo-controlled phase 3 PACIFIC trial, the P...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190020/ https://www.ncbi.nlm.nih.gov/pubmed/33881745 http://dx.doi.org/10.1007/s12325-021-01675-0 |